AUTHOR OF THIS BLOG

DR ANTHONY MELVIN CRASTO, WORLDDRUGTRACKER
Dec 212016
 

str00

 COSY PREDICT

str0

                      

1H NMR PREDICT

 

str1

str1

                      

 

str1

1H NMR (DMSO-d6, 400 MHz): δH 0.95 (3H, d, H4), 3.09–3.23 (2H, m, H2), 3.29–3.49 (5H, m, H14, H11, H3), 3.94–4.04 (2H, m, H5), 8.14 (1H, s, H8), 8.02 (1H, s, H9).

 

 

                      

13C NMR PREDICT

str1 str2

                      

str2

13C NMR (DMSO-d6, 100 MHz): δC 50.54 (C2), 54.33 (C3), 11.28 (C4), 52.31 (C5), 166.81 (C6), 147.15 (C7), 128.95 (C8), 135.96 (C9), 147.07 (C10), 51.93 (C11, C14), 172.41 (C12, C13);

str3 str4

 

str1 str2

                      

 

Figure

Houben-Weyl methods of organic chemistry, 4th ed.; Vol. E 9c Hetarenes III part 3; p 279.

5-(2-(3-Oxopiperazin-1-yl) propyl)-5,6-dihydropteridin-7(8H)-one (Impurity A)

M.p.: 252.09 °C.
1H NMR (DMSO-d6, 400 MHz): δH 0.95 (3H, d, H4), 3.09–3.23 (2H, m, H2), 3.29–3.49 (5H, m, H14, H11, H3), 3.94–4.04 (2H, m, H5), 8.14 (1H, s, H8), 8.02 (1H, s, H9).
13C NMR (DMSO-d6, 100 MHz): δC 50.54 (C2), 54.33 (C3), 11.28 (C4), 52.31 (C5), 166.81 (C6), 147.15 (C7), 128.95 (C8), 135.96 (C9), 147.07 (C10), 51.93 (C11, C14), 172.41 (C12, C13);
                       
str3
HRMS (ESI) calcd for C13H17O3N6: 305. 13338 ([M + H]+), found; 305.13566([M + H]+).
IR (KBr, cm–1): 3248.13 (NH), 2970.38 and 2931.80 (CH), 1705.07 and 1689.64 (C═O), 1564.27 (NH bending), 1512.19 (C═N).

                       

Study on the Isolation and Chemical Investigation of Potential Impurities in Dexrazoxane Using 2D-NMR and LC-PDA-MS

§ Centre for Chemical Science & Technology, Institute of Science & Technology, Jawaharlal Nehru Technological University, Hyderabad 500085, Telangana, India
Gland Pharma Ltd, Research and Development, D.P.Pally, Hyderabad 500043, Telangana, India
Org. Process Res. Dev., Article ASAP
DOI: 10.1021/acs.oprd.6b00219
Publication Date (Web): December 7, 2016
Copyright © 2016 American Chemical Society
*E-mail: venkatesan@glandpharma.com. Phone: 040-30510999 Ext: 280. Fax: 30510800., *E-mail: maheshk@glandpharma.com. Phone: 040-30510999 Ext: 280. Fax: 30510800.
guvvala vinodh
Abstract Image

A chemical investigation of process related impurities associated with the synthesis of dexrazoxane was performed. The degradation product of dexrazoxane is known in the literature; however, the information related to process impurities is not available. For the first time, two process related impurities were isolated, characterized, and confirmed by their individual chemical synthesis. The present study describes the isolation methods of the impurities and their structural elucidation using IR, 1H, 13C, 2D NMR, and mass spectrometry. The identification of these impurities would be highly valuable for the quality control during the production of the dexrazoxane drug substance

The U.S. Food and Drug Administration (FDA)(5) and the European Medicine Agency (EMA)(6) require analytical characterization not only for the active pharmaceutical ingredient (API), but also for its key starting materials and advanced intermediates. The determination of a drug substance impurity profile, including especially known pharmacopeial impurities, as well as other unknown impurities, could have a significant impact on the quality and the safety of the drug products. The health implications of the impurities could be significant because of their potential mutagenic or carcinogenic effects. Therefore, the International Conference on Harmonization (ICH) has set a high standard for the purity of drug substances.(7) If the dose is less than 2 g/day, then impurities over 0.10% are expected to be identified, qualified, and controlled. If the dose exceeds 2 g/day, then the qualification threshold is lowered to 0.05%. It is therefore essential to monitor and control the impurities in both the drug substance (API) and the drug products.

  1. 5 Guidance for Industry on Abbreviated New Drug Applications: Impurities in Drug Substances; Availability;Fed. Regist. 2009, 74, 3435934360.

  2. 6.The International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline: Impurities in New Drug Substances Q3A (R2); IGH: Geneva, Switzerland, 2006.

  3. 7.International Conference on Harmonization; revised guidance on Q3A impurities in new drug Substances; Availability; Fed. Regist. 2003, 68, 69246925.

//////////5-(2-(3-Oxopiperazin-1-yl) propyl)-5,6-dihydropteridin-7(8H)-one

O=C1Nc3ncncc3N(C1)[C@@H](C)CN2CC(=O)NC(=O)C2

Share

Sorry, the comment form is closed at this time.

Follow

Get every new post on this blog delivered to your Inbox.

Join other followers: